Arca
Skip to content
Tools
Tools

Chronic progressive multiple sclerosis

Drug research and approvals for chronic progressive multiple sclerosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 37 studies of chronic progressive multiple sclerosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.

  • Recruiting worldwide: 37
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 37 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 3

  • OcrelizumabB-lymphocyte antigen CD20 binding agent
  • SiponimodSphingosine 1-phosphate receptor Edg-1 agonist
  • UblituximabB-lymphocyte antigen CD20 binding agent

Phase 3 12 of 17

Phase 2 12 of 20

Phase 1 or earlier 12 of 15

How its trials ended

207 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 42 whose ending is known, 31% met their primary endpoint, 24% missed it and 45% stopped early.

  • Completed, result not reported8039%
  • Ongoing6330%
  • Status unknown2211%
  • Met its primary endpoint136%
  • Missed its primary endpoint105%
  • Stopped: other or unclear84%
  • Stopped: lack of efficacy63%
  • Stopped: enrollment or feasibility21%
  • Stopped: sponsor or business decision21%
  • Stopped: funding1<1%

FDA orphan designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Dec 9, 1985ColchicineFor arresting the progression of neurologic disability caused by chronic progressive multiple sclerosis.Pharmacontrol CorporationDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.